En vivo
FierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization10x Genomics News10x Genomics acquires Proteintech Genomics division - Investing.comPharmaVoiceWith a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its markPharmaVoiceWill obesity drugs save Pfizer from its post-COVID slump?10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - TradingViewPromega BlogThe Molecular Blueprint for Virus-Resistant CowpeaFierceBiotechWith ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity raceFierceBiotechThe new standard for trusted AI in biopharmaEndpoints NewsPost-Hoc Live: How much is everyone in biopharma getting paid?BioWorldAppointments and advancements for June 9, 2026BioWorldFinancings for June 9, 2026BioWorldIn the clinic for June 9, 2026
Endpoints News 26 nov 2025

China's Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturna

China's Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturna

Contenido no disponible. Consulta la fuente original.